A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma

Hematological Oncology

Volumn 25, Issue 3, 2007, Pages 107-114

  Tsurumi, Hisashi ^a   Hara, Takeshi ^a   Goto, Naoe ^a   Kanemura, Nobuhiro ^a   Kasahara, Senji ^a   Sawada, Michio ^a   Yasuda, Ichiro ^a   Yamada, Toshiki ^a   Shimizu, Masahito ^a   Takami, Tsuyoshi ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CHOP; Elderly; non Hodgkin's lymphoma; Pirarubicin; THP COP

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISOLONE; SEROTONIN 3 ANTAGONIST; VINCRISTINE;

AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HEMATURIA; HERPES ZOSTER; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; NEUTROPENIA; PREDNISOLONE; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 34848831741     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.815     Document Type: Article

References (34)

1. Carbone A, Volper R, Gloghini A, et al. Non-Hodgkin's lymphoma in the elderly: I. pathological features at presentation. Cancer 1990; 66: 1991-1996.
2. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-1844.
3. Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 1979; 32: 1082-1084.
4. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994; 22: 261-268.
5. Takagi T, Oguro M. (2″-R)-4′-o-Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 1987; 20: 151-154.
6. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004; 130: 107-113.
7. Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin, in THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990; 13(Suppl. 1): S15-S19.
8. Niitsu N, Umeda M. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 1997; 11: 1817-1820.
9. Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005; 81: 246-254.
10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
11. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors, Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001; 109-236.
13. Sawada M, Tsurumi H, Yamada T, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002; 68: 354-361.
14. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Cox DR. Regression models and life-tables (with discussions). J Roy Stat Soc (Series B) 1972; 34: 187-220.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
18. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
19. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945-2953.
20. Bessell EM, Coutts A, Fletcher J, et al. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology. Eur J Cancer 1994; 3OA: 1337-1341.
21. Mori M, Niitsu N, Takagi T, et al. Reduced-dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 41: 359-366.
22. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269-273.
23. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the South-west Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
24. d'Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann Oncol 1992; 3: 379-386.
25. Tirelli U, Zagonel V, Serraino D, et al. Non-Hodgkin's lymphoma in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. J Clin Oncol 1998; 6: 1708-1713.
26. Niitsu N, Iijima K. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study. Ann Hematol 2001; 80: 602-606.
27. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-3050.
28. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5: 895-900.
29. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996; 22: 483-493.
30. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-4311.
31. Pfreundschuh M, Trumper L, Kloess M, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group: two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
32. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
33. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003; 17: 1948-1960.
34. Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 1998; 17: 465-470.